IGF2 and prostate carcinoma: It has previously been shown that loss of imprinting (LOI)‐independent hypomethylation of P3 induces IGF2 expression in osteosarcoma, and ovarian and prostate cancer (Kuffer et al., 2018; Li et al., 2009; Murphy et al., 2006); however, several transcription factors have been known to regulate P3 methylation and activity, for example, Paxillin, STAT3, and PLAG1 (Akhtar et al., 2012; Huang et al., 2014; Lee et al., 2016; Marasek et al., 2015).